Encompass Health (NYSE:EHC) Price Target Raised to $116.00

Encompass Health (NYSE:EHC) had its price target upped by Barclays from $109.00 to $116.00 in a report published on Tuesday, Benzinga reports. The brokerage currently has an overweight rating on the stock.

Several other brokerages also recently weighed in on EHC. KeyCorp increased their target price on shares of Encompass Health from $115.00 to $117.00 and gave the company an “overweight” rating in a research note on Tuesday. Leerink Partnrs raised shares of Encompass Health to a “strong-buy” rating in a research note on Wednesday, July 10th. Royal Bank of Canada upped their target price on Encompass Health from $95.00 to $105.00 and gave the company an “outperform” rating in a research note on Thursday, September 26th. Truist Financial raised their price target on Encompass Health from $104.00 to $108.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Finally, Leerink Partners began coverage on Encompass Health in a research report on Wednesday, July 10th. They issued an “outperform” rating and a $100.00 price objective on the stock. Nine research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $107.11.

Encompass Health Stock Performance

Encompass Health stock opened at $98.88 on Tuesday. The company has a quick ratio of 1.35, a current ratio of 1.04 and a debt-to-equity ratio of 0.88. Encompass Health has a twelve month low of $62.58 and a twelve month high of $102.36. The company’s 50-day moving average price is $94.47 and its 200-day moving average price is $88.82. The company has a market cap of $9.95 billion, a PE ratio of 23.88, a price-to-earnings-growth ratio of 1.47 and a beta of 0.88.

Encompass Health (NYSE:EHC) last issued its quarterly earnings data on Monday, October 28th. The company reported $1.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.94 by $0.09. The business had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.33 billion. Encompass Health had a return on equity of 17.60% and a net margin of 8.10%. The company’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same period in the prior year, the business posted $0.86 earnings per share. On average, equities research analysts forecast that Encompass Health will post 4.27 EPS for the current fiscal year.

Encompass Health announced that its Board of Directors has initiated a stock repurchase plan on Wednesday, July 24th that authorizes the company to buyback $500.00 million in outstanding shares. This buyback authorization authorizes the company to reacquire up to 5.4% of its shares through open market purchases. Shares buyback plans are often a sign that the company’s management believes its shares are undervalued.

Encompass Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Thursday, January 2nd will be paid a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a yield of 0.69%. The ex-dividend date is Thursday, January 2nd. Encompass Health’s dividend payout ratio (DPR) is 16.43%.

Insider Activity

In other Encompass Health news, CFO Douglas E. Coltharp sold 12,260 shares of the business’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $86.34, for a total value of $1,058,528.40. Following the completion of the transaction, the chief financial officer now directly owns 136,227 shares in the company, valued at approximately $11,761,839.18. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 2.10% of the company’s stock.

Institutional Investors Weigh In On Encompass Health

Institutional investors have recently bought and sold shares of the company. UMB Bank n.a. boosted its position in shares of Encompass Health by 387.7% in the 3rd quarter. UMB Bank n.a. now owns 317 shares of the company’s stock worth $31,000 after purchasing an additional 252 shares in the last quarter. V Square Quantitative Management LLC boosted its holdings in Encompass Health by 53.0% in the third quarter. V Square Quantitative Management LLC now owns 404 shares of the company’s stock worth $39,000 after acquiring an additional 140 shares in the last quarter. Oakworth Capital Inc. acquired a new stake in Encompass Health in the 2nd quarter worth approximately $40,000. Benjamin F. Edwards & Company Inc. grew its holdings in shares of Encompass Health by 58.9% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 534 shares of the company’s stock valued at $46,000 after buying an additional 198 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Encompass Health in the second quarter valued at about $58,000. 97.25% of the stock is currently owned by institutional investors and hedge funds.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.